A Study to Evaluate ONM100, an Intraoperative Fluor Imaging Agent for the Detection of Peri Mets

Completed · Phase 2

Conditions studied: Peritoneal Carcinomatosis

In brief

Peritoneal carcinomatosis (PC) results from the metastasis of a primary cancer of the peritoneum (e.g., appendiceal, ovarian, uterine, colorectal, and gastric cancers) that then disseminates throughout the abdominal cavity. Historically progression to PC was considered terminal and resulted in survival times on the scale of a few months with palliative care being the best option for patients. More recently, cytoreductive surgery (CS) has emerged as a means to prolong and improve patient lives with a median increase in survival of up to \~5 years. It has been reported that for every 10% increase in cytoreduction there is a 5.5% increase in median survival time. In addition to surgical tumor debulking within the peritoneal space, it has also been shown that coupling surgical intervention with hyperthermic intraperitoneal chemotherapy (HIPEC) can have an even greater impact on patient outcomes. Pegsitacianine, a micellar fluorescence agent, exploits the ubiquitous pH differences observed between cancerous and normal tissues. This in turn, provides a highly sensitive and specific fluorescence response after localizing within the tumor microenvironment, thus allowing the detection of primary tumors, their margins, metastatic disease, and tumor-containing lymph nodes.

Key facts

Study ID

NCT04950166

Run by

OncoNano Medicine, Inc.

People needed

51

Starts

2021-11-30

Expected to finish

2023-01-20

Last updated by the study team

2024-11-08

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Imaging and biopsy confirmed metastatic disease of peritoneal origin

You may not qualify if…

• Known hypersensitivity or allergy to any component of pegsitacianine
• Tumor locations the surgeon deems unfeasible to image intraoperatively
• Excessive and/or generalized metastatic disease deemed inoperative by the surgeon

Where it is running

• Wake Forest Baptist Health — Winston-Salem, North Carolina, United States
• The Ohio State University Wexner Medical Center / James Cancer Hospital — Columbus, Ohio, United States
• Perelman School of Medicine, University of Pennsylvania — Philadelphia, Pennsylvania, United States
• AHN Cancer Institute, West Penn Hospital — Pittsburgh, Pennsylvania, United States
• The University of Texas MD Anderson Cancer Center — Houston, Texas, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.